Partner with us for cell line and strain development, manufacturability assessments, cell banking and toxicology material generation. Let us guide your path to IND/IMPD submission.
Partner with us for process validation and process performance qualification. Leverage our CMC and regulatory services for your BLA/MAA submission and experience our reliability.
HOLLY SPRINGS, N.C., April 22, 2025 – FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced a 10-year manufacturing supply agreement, valued at over $3 billion, with Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to provide U.S.-based production of its industry-leading biologic medicines, which treat millions of patients worldwide.
HILLERØD, DENMARK, January 9, 2025 — The Danish life science industry is getting yet another boost as FUJIFILM Diosynth Biotechnologies celebrates its recent production expansion in Denmark.
THOUSAND OAKS, CALIF., November 20, 2024 – FUJIFILM Diosynth Biotechnologies today hosted a celebration for the completion of an expansion of its cell therapy manufacturing facility in Thousand Oaks, California.
HILLERØD, DENMARK, November 5, 2024 – FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic viruses, proudly announces that the first phase of its expansion at the Hillerød site is ready to bring the new production capacity into operation.